Skip to main content

The Cooper Companies guidance

  • COO · Nasdaq
  • Medical devices
  • Health Care Supplies
  • S&P 500
$61.88−1.23%Close 16 Nov 2026 · Market value $11.64B · Next results 3 Dec 2026

In its results release of 9 Sep 2026 (Q3 FY2026), The Cooper Companies gave 6 forecasts in figures, among them revenue of $1.06B to $1.08B for Q4 FY2026. Over the last two years, results landed above the company's own last range 2 of 5 times, within it 3 and below it 0.

Read from the company's earnings releases and outlook updates of the last two years. Each forecast is shown with the sentence or table row it was read from; what a release does not state in figures is not shown.

Latest guidance given with Q3 FY2026 results, 9 Sep 2026

MeasurePeriodGuidanceAs stated
RevenueQ4 FY2026$1.06B to $1.08BFiscal fourth quarter 2026 total revenue of $1.057 - $1.080 billion (organic growth of 0% to 2%)
Revenue growthQ4 FY20260% to +2%Fiscal fourth quarter 2026 total revenue of $1.057 - $1.080 billion (organic growth of 0% to 2%)
EPS · AdjustedQ4 FY2026$1.05 to $1.09Fiscal fourth quarter 2026 non-GAAP diluted EPS of $1.05 -$1.09
RevenueFY2026$4.23B to $4.25BFiscal 2026 total revenue of $4.229 - $4.252 billion (organic growth of 2% to 3%)
Revenue growthFY2026+2% to +3%Fiscal 2026 total revenue of $4.229 - $4.252 billion (organic growth of 2% to 3%)
EPS · AdjustedFY2026$4.51 to $4.55Fiscal 2026 non-GAAP diluted EPS of $4.51 - $4.55

Source: the company's earnings release.

Guidance against results above 2 · within 3 · below 0

The last range given before each period closed, how it moved between releases, and the figure then filed. A measure the company defines itself, or one not comparable with the filed figure, has no verdict.

MeasurePeriodLast guidanceRevisionsDeliveredResult
RevenueFY2026$4.23B to $4.25BRaised once, lowered twice—To come
Revenue growthFY2026+2% to +3%Lowered twice—To come
EPS · AdjustedFY2026$4.51 to $4.55Raised once, lowered once—To come
Free cash flowFY2026$600M to $625MRaised once—To come
RevenueQ4 FY2026$1.06B to $1.08BGiven once—To come
Revenue growthQ4 FY20260% to +2%Given once—To come
EPS · AdjustedQ4 FY2026$1.05 to $1.09Given once—To come
RevenueQ1 FY2026$1.02B to $1.03BGiven once$1.02BWithin the range
Revenue growthQ1 FY2026+3% to +4%Given once+6.16%Above the range
EPS · AdjustedQ1 FY2026$1.02 to $1.04Given once$1.10Above the range
RevenueFY2025$4.08B to $4.10BRaised once, lowered once$4.09BWithin the range
Revenue growthFY2025+4% to +4.5%Lowered twice+5.06%Above the range
RevenueQ4 FY2025$1.05B to $1.07BGiven once$1.07BWithin the range
Revenue growthQ4 FY2025+2% to +4%Given once+4.59%Above the range
EPS · AdjustedQ4 FY2025$1.10 to $1.14Given once$1.15Above the range

COO in the terminal

Guidance said on earnings calls, every revision charted, and guidance set against the analysts' consensus.